FR08C0025I1 - Heterocycles bicycliques disubstitues, production et utilisation comme medicaments - Google Patents
Heterocycles bicycliques disubstitues, production et utilisation comme medicamentsInfo
- Publication number
- FR08C0025I1 FR08C0025I1 FR08C0025C FR08C0025I1 FR 08C0025 I1 FR08C0025 I1 FR 08C0025I1 FR 08C0025 C FR08C0025 C FR 08C0025C FR 08C0025 I1 FR08C0025 I1 FR 08C0025I1
- Authority
- FR
- France
- Prior art keywords
- drugs
- production
- bicyclic heterocycles
- disubstituted bicyclic
- disubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/74—Sulfur atoms substituted by carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19706229A DE19706229A1 (de) | 1997-02-18 | 1997-02-18 | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE1997151939 DE19751939A1 (de) | 1997-11-24 | 1997-11-24 | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
PCT/EP1998/000865 WO1998037075A1 (fr) | 1997-02-18 | 1998-02-16 | Heterocycles bicycliques disubstitues, production et utilisation comme medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
FR08C0025I1 true FR08C0025I1 (fr) | 2008-07-18 |
FR08C0025I2 FR08C0025I2 (fr) | 2009-11-20 |
Family
ID=26034058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR08C0025C Active FR08C0025I2 (fr) | 1997-02-18 | 2008-06-06 | Heterocycles bicycliques disubstitues, production et utilisation comme medicaments |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP0966454B1 (fr) |
JP (1) | JP3343359B2 (fr) |
KR (1) | KR100619458B1 (fr) |
CN (1) | CN1088702C (fr) |
AR (1) | AR010896A1 (fr) |
AT (1) | ATE239712T1 (fr) |
AU (1) | AU742593C (fr) |
BG (1) | BG64558B1 (fr) |
BR (1) | BR9807843B1 (fr) |
CA (1) | CA2277949C (fr) |
CO (1) | CO4920237A1 (fr) |
CZ (1) | CZ297768B6 (fr) |
DE (2) | DE122008000020I1 (fr) |
DK (1) | DK0966454T3 (fr) |
EA (1) | EA003697B1 (fr) |
EE (1) | EE04716B1 (fr) |
EG (1) | EG24144A (fr) |
ES (1) | ES2199426T4 (fr) |
FR (1) | FR08C0025I2 (fr) |
HK (1) | HK1025096A1 (fr) |
HR (1) | HRP980082B1 (fr) |
HU (1) | HU223754B1 (fr) |
IL (1) | IL130812A (fr) |
LT (1) | LTC0966454I2 (fr) |
LU (1) | LU91437I2 (fr) |
MY (1) | MY129408A (fr) |
NL (1) | NL300349I2 (fr) |
NO (3) | NO313879B1 (fr) |
NZ (1) | NZ337323A (fr) |
PE (1) | PE121699A1 (fr) |
PL (1) | PL195551B1 (fr) |
PT (1) | PT966454E (fr) |
RS (1) | RS49686B (fr) |
SA (1) | SA98190047B1 (fr) |
SI (1) | SI0966454T1 (fr) |
SK (1) | SK285432B6 (fr) |
TR (1) | TR199902017T2 (fr) |
TW (1) | TW588047B (fr) |
WO (1) | WO1998037075A1 (fr) |
Families Citing this family (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1608399A (en) * | 1997-11-26 | 1999-06-15 | Axys Pharmaceuticals, Inc. | Substituted amidinoaryl derivatives and their use as anticoagulants |
EP1060166A1 (fr) * | 1998-02-03 | 2000-12-20 | Boehringer Ingelheim Pharma KG | Heterocycles benzo condenses a 5 chainons utilises comme agents antithrombotiques |
US6114532A (en) * | 1998-02-03 | 2000-09-05 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals |
CA2321025A1 (fr) * | 1998-02-09 | 1999-08-12 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines et guanidines utiles en tant qu'inhibiteurs de protease et plus particulierement en tant qu'inhibiteurs d'urokinase |
US6291514B1 (en) | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
TWI248435B (en) * | 1998-07-04 | 2006-02-01 | Boehringer Ingelheim Pharma | Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions |
US6248770B1 (en) | 1998-07-09 | 2001-06-19 | Boehringer Ingelheim Pharma Kg | Benzimidazoles having antithrombotic activity |
PL351767A1 (en) * | 1999-02-09 | 2003-06-16 | Dimensional Pharmaceuticals 3 | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors |
DE19907813A1 (de) * | 1999-02-24 | 2000-08-31 | Boehringer Ingelheim Pharma | Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel |
AR023510A1 (es) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
DE19939463A1 (de) * | 1999-08-20 | 2001-02-22 | Boehringer Ingelheim Pharma | Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US6512000B1 (en) | 1999-08-20 | 2003-01-28 | Boehringer Ingelheim Pharma Kg | Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity |
DK1220844T3 (da) * | 1999-09-24 | 2003-07-28 | Boehringer Ingelheim Pharma | Arylsulfonamid-substituerede benzimidazolderivater og deres anvendelse som tryptase-inhibitorer |
DE19945787A1 (de) | 1999-09-24 | 2001-03-29 | Boehringer Ingelheim Pharma | Arylsulfonamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE19945810A1 (de) * | 1999-09-24 | 2001-03-29 | Boehringer Ingelheim Pharma | Substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US6413990B1 (en) | 1999-09-24 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Arylsulphonamide-substituted benzimidazoles having tryptase-inhibiting activity |
US6407130B1 (en) | 1999-11-10 | 2002-06-18 | Boehringer Ingelheim Pharma Kg | Carboxamide-substituted benzimidazoles having tryptase-inhibiting activity |
US6451832B2 (en) | 1999-12-23 | 2002-09-17 | Boehringer Ingelheim Pharma Kg | Benzimidazoles with antithrombotic activity |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
EP1614680B1 (fr) * | 2001-04-19 | 2011-12-21 | Eisai R&D Management Co., Ltd. | Procédé de préparation de dérivés de la 2-iminopyrrolidine |
DE10133786A1 (de) * | 2001-07-16 | 2003-02-06 | Boehringer Ingelheim Pharma | Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
CA2476054C (fr) * | 2002-03-07 | 2011-11-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Forme pharmaceutique pour administration orale a base d'ethylester d'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionique ou dw ses sels pharmaceutiquement acceptables |
DE10235639A1 (de) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO2004014844A2 (fr) | 2002-08-09 | 2004-02-19 | Transtech Pharma, Inc. | Composes aryle et heteroaryle et procedes de modulation de la coagulation |
PE20040804A1 (es) | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
DE10260730A1 (de) | 2002-12-23 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte stickstoffhaltige Heterobicyclen, deren Herstellung und deren Verwendung als Arzneimittel |
US7429597B2 (en) | 2002-12-23 | 2008-09-30 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions |
CN100439336C (zh) | 2003-02-19 | 2008-12-03 | 卫材R&D管理有限公司 | 制备环状苯甲脒衍生物的方法 |
DE10310278A1 (de) * | 2003-03-10 | 2004-09-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue aromatische Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel |
MXPA05011432A (es) * | 2003-04-24 | 2006-03-21 | Boehringer Ingelheim Int | Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. |
US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ,インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
DE10339862A1 (de) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
DE10341043A1 (de) * | 2003-09-03 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze |
EP1609784A1 (fr) * | 2004-06-25 | 2005-12-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | Procédé pour la préparation de 4-(benzimidazolylméthylamino)-benzamidines |
US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
DE102005020002A1 (de) * | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
DE102005025728A1 (de) | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester |
DE602006017694D1 (de) | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
DE102005061624A1 (de) | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen |
DE102005061623A1 (de) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen |
US8044242B2 (en) | 2006-03-09 | 2011-10-25 | Bristol-Myers Squibb Company | 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants |
US8222453B2 (en) | 2006-06-08 | 2012-07-17 | Bristol-Myers Squibb Company | Benzamide factor VIIa inhibitors useful as anticoagulants |
CA2657269A1 (fr) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | Nouvelles indications portant sur les inhibiteurs directs de la thrombine |
CA2657266A1 (fr) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | Nouvelles indications portant sur les inhibiteurs directs de la thrombine dans le domaine cardiovasculaire |
WO2008043759A1 (fr) * | 2006-10-10 | 2008-04-17 | Boehringer Ingelheim International Gmbh | Sels physiologiquement acceptables de l'ester éthylique de l'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino-méthyl)-phénylamino]-méthyl}-1-méthyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionique. |
EP2102189B1 (fr) | 2006-12-15 | 2015-07-29 | Bristol-Myers Squibb Company | Analogues d'arylpropionamide, d'arylacrylamide, d'arylpropynamide ou d'arylméthylurée en tant qu'inhibiteurs du facteur xia |
PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
EP1956018A1 (fr) * | 2007-02-06 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Procédé de préparation d'un dérivé du benzimidazole |
KR20100015886A (ko) | 2007-04-23 | 2010-02-12 | 사노피-아벤티스 | P2y12 길항제로서의 퀴놀린-카복스아미드 유도체 |
EP2178849A1 (fr) | 2007-07-31 | 2010-04-28 | Mallinckrodt Inc. | Agents photoactifs intégrés et leurs utilisations |
WO2009080226A2 (fr) | 2007-12-26 | 2009-07-02 | Sanofis-Aventis | Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12 |
CZ305085B6 (cs) * | 2008-03-14 | 2015-04-29 | Zentiva, K.S. | Způsob přípravy dabigatranu |
TWI436994B (zh) * | 2008-07-14 | 2014-05-11 | Boehringer Ingelheim Int | 製備含有達比加群(dabigatran)之藥物組合物的新穎方法 |
US20110190352A1 (en) * | 2008-08-19 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
CZ2008669A3 (cs) * | 2008-10-24 | 2010-05-05 | Zentiva, A. S. | Zpusob prípravy dabigatranu a jeho meziprodukty |
EP2391893B1 (fr) | 2009-02-02 | 2014-09-03 | Boehringer Ingelheim International GmbH | Dabigatran lyophilisé |
EP2429520A1 (fr) | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | Nouvelle polytherapie destinee a traiter les maladies oncologiques et fibrotiques |
BR112012004169A2 (pt) | 2009-08-24 | 2016-03-29 | Boehringer Ingelheim Int | intervenções de emergência com carvão vegetal ativado em superdosagem de etexilato de dabigatran |
CN102050815B (zh) * | 2009-11-06 | 2014-04-02 | 北京美倍他药物研究有限公司 | 作为前药的达比加群的酯衍生物 |
CN102050814B (zh) * | 2009-11-06 | 2014-05-28 | 北京美倍他药物研究有限公司 | 达比加群的酯衍生物 |
US8399678B2 (en) | 2009-11-18 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dabigatran etexilate |
AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
HUP1000069A2 (en) | 2010-02-02 | 2012-05-02 | Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag | New salts for the preparation of pharmaceutical composition |
TWI577665B (zh) | 2010-02-11 | 2017-04-11 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之巨環類 |
EP2542224B1 (fr) | 2010-03-01 | 2014-08-13 | Ratiopharm GmbH | Composition pharmaceutique à voie orale contenant d'éxilate de dabigatrane |
CA2792273A1 (fr) | 2010-03-08 | 2011-09-15 | Ratiopharm Gmbh | Composition pharmaceutique contenant du dabigatran etexilate |
ES2631980T3 (es) | 2010-07-01 | 2017-09-07 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables |
EP2937343A1 (fr) | 2010-07-09 | 2015-10-28 | Esteve Química, S.A. | Procédé de préparation d'un inhibiteur spécifique de la thrombine |
WO2012004397A1 (fr) | 2010-07-09 | 2012-01-12 | Esteve Química, S.A. | Intermédiaires et procédé de préparation d'un inhibiteur spécifique de la thrombine |
WO2012027543A1 (fr) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Formes solides de dabigatran étexilate et de dabigatran étexilate mésylate et leurs méthodes de préparation |
WO2012077136A2 (fr) | 2010-12-06 | 2012-06-14 | Msn Laboratories Limited | Procédé de préparation de dérivés de benzimidazole et de leurs sels |
US9000186B2 (en) | 2011-02-01 | 2015-04-07 | Kyowa Hakko Kirin Co., Ltd. | Ring-fused heterocyclic derivative |
EP2691156A1 (fr) | 2011-03-30 | 2014-02-05 | Boehringer Ingelheim International GmbH | Antidotes aux anticoagulants |
HUP1100244A2 (hu) | 2011-05-11 | 2012-11-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Gyógyszeripari intermedierek és eljárás elõállításukra |
CN102250099B (zh) * | 2011-05-16 | 2013-10-16 | 中国药科大学 | 一类非肽类抗凝血酶抑制剂、其制法以及医药用途 |
CN102838588B (zh) * | 2011-06-24 | 2014-03-19 | 中国药科大学 | 一类可用于口服的凝血酶抑制剂、其制法以及医药用途 |
ES2611610T3 (es) * | 2011-07-25 | 2017-05-09 | Develco Pharma Schweiz Ag | Ésteres de ácidos amidoxima-carboxílicos de dabigatrán como profármacos y su utilización como un medicamento |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
WO2013024394A1 (fr) * | 2011-08-12 | 2013-02-21 | Alembic Pharmaceuticals Limited | Nouveaux marqueurs de référence d'étéxilate de dabigatran |
CN102993175B (zh) * | 2011-09-08 | 2014-08-13 | 天津药物研究院 | 达比加群的酯衍生物及其制备方法和用途 |
CN102993174A (zh) * | 2011-09-08 | 2013-03-27 | 天津药物研究院 | 作为前药的达比加群的酯衍生物 |
CN103987696B (zh) | 2011-10-14 | 2016-12-21 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
PL2766346T3 (pl) | 2011-10-14 | 2017-09-29 | Bristol-Myers Squibb Company | Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA |
ES2699226T3 (es) | 2011-10-14 | 2019-02-08 | Bristol Myers Squibb Co | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa |
JP2015500853A (ja) | 2011-12-22 | 2015-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 即時放出マルチユニットペレットシステム |
US9212166B2 (en) | 2012-01-20 | 2015-12-15 | Cadila Healthcare Limited | Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof |
WO2013110567A1 (fr) | 2012-01-24 | 2013-08-01 | Boehringer Ingelheim International Gmbh | Nouvelle formulation de dabigatran à administration par voie orale |
JP6215239B2 (ja) | 2012-02-21 | 2017-10-18 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | ダビガトランエテキシラートの経口医薬組成物 |
EP2631234A1 (fr) | 2012-02-23 | 2013-08-28 | Esteve Química, S.A. | Formes solides de mesylate d'étexilate de dabigatran et leurs procédés de préparation |
WO2013144971A1 (fr) | 2012-03-27 | 2013-10-03 | Cadila Healthcare Limited | Nouvelles formes solides de bisulfate et de mésylate d'étéxilate de dabigatran, et leurs procédés de préparation |
EP2834224B1 (fr) | 2012-04-02 | 2018-06-06 | MSN Laboratories Limited | Procédés de préparation de dérivés de benzimidazole et de sels de ceux-ci |
CN103387566B (zh) * | 2012-05-09 | 2015-09-09 | 上海医药工业研究院 | 制备3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1h-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯的方法 |
CN103420980A (zh) * | 2012-05-22 | 2013-12-04 | 北京美倍他药物研究有限公司 | 达比加群衍生物 |
WO2014001220A1 (fr) | 2012-06-25 | 2014-01-03 | Boehringer Ingelheim International Gmbh | Procédé de prévention d'un accident vasculaire cérébral |
JP2015522596A (ja) * | 2012-07-16 | 2015-08-06 | インテルキム、ソシエダッド アノニマ | ダビガトランエテキシラートの合成のための中間体を調製する方法及び該中間体の結晶形 |
CN102766134B (zh) * | 2012-07-19 | 2014-06-25 | 北京普禄德医药科技有限公司 | 达比加群的酯衍生物及其制备方法和用途 |
WO2014021383A1 (fr) * | 2012-07-31 | 2014-02-06 | 協和発酵キリン株式会社 | Composé hétérocyclique à cycles condensés |
CN108250199B (zh) | 2012-08-03 | 2021-07-16 | 百时美施贵宝公司 | 二氢吡啶酮p1作为凝血因子xia抑制剂 |
UY34959A (es) | 2012-08-03 | 2014-01-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Dihidropiridona p1 como inhibidores del factor xia |
WO2014041559A2 (fr) * | 2012-08-27 | 2014-03-20 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Procédé de préparation d'étéxilate de dabigatran et ses intermédiaires |
WO2014060561A1 (fr) | 2012-10-19 | 2014-04-24 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Formulations pharmaceutiques orales contenant du dabigatran |
WO2014060545A1 (fr) | 2012-10-19 | 2014-04-24 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Compositions pharmaceutiques de dabigatran sous forme de base libre |
US9399616B2 (en) | 2012-10-22 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of 4-aminobenzoamidine dihydrochloride |
US10077251B2 (en) | 2012-10-29 | 2018-09-18 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the synthesis of Dabigatran Etexilate and its intermediates |
WO2014068587A2 (fr) * | 2012-10-29 | 2014-05-08 | Biophore India Pharmaceuticals Pvt. Ltd. | Procédé amélioré de synthèse du dabigatran et de ses intermédiaires |
CN102977077A (zh) * | 2012-11-28 | 2013-03-20 | 浙江燎原药业有限公司 | 一种达比加群酯中间体的制备方法 |
EP2740471B1 (fr) | 2012-12-07 | 2015-05-27 | Hexal AG | Composition pharmaceutique orale comprenant le dabigatran etexilate |
CN103044404A (zh) * | 2013-01-14 | 2013-04-17 | 中国药科大学 | 达比加群衍生物、其制法及抗血栓用途 |
EP2978751B1 (fr) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tétrahydroisoquinolines comprenant des azoles substitués en tant qu'inhibiteurs du facteur xia |
CN103224469A (zh) * | 2013-05-16 | 2013-07-31 | 上海应用技术学院 | 一种以含氟基团修饰的苯环为中心的达比加群酯类似物及其合成方法 |
WO2014195230A1 (fr) | 2013-06-03 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Benzoxazoles substitués |
UY35592A (es) * | 2013-06-03 | 2014-12-31 | Bayer Pharma AG | Benzoxazoles sustituidos |
CN103288744A (zh) * | 2013-06-04 | 2013-09-11 | 上海应用技术学院 | 一种含氟基团修饰的达比加群酯类似物及其合成方法 |
EP2853260A1 (fr) | 2013-09-27 | 2015-04-01 | ratiopharm GmbH | Préparation pharmaceutique comprenant du dabigatran etexilate bismésylate |
HUE040226T2 (hu) | 2014-01-31 | 2019-02-28 | Bristol Myers Squibb Co | Makrociklusok heterociklusos P2' csoportokkal XIA faktor inhibitorokként |
NO2760821T3 (fr) | 2014-01-31 | 2018-03-10 | ||
WO2015128875A2 (fr) | 2014-02-26 | 2015-09-03 | Megafine Pharma (P) Ltd. | Procédé de préparation de dabigatran étéxilate mésylate et de ses intermédiaires |
WO2015137680A1 (fr) * | 2014-03-10 | 2015-09-17 | 동아에스티 주식회사 | Composition pharmaceutique de traitement ou de prévention d'un accident vasculaire cérébral et de l'embolie systémique |
WO2015145462A1 (fr) | 2014-03-26 | 2015-10-01 | Cadila Healthcare Limited | Compositions pharmaceutiques de dabigatran |
WO2015155281A1 (fr) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Combinaisons pharmaceutiques de dabigatran et d'inhibiteurs de la pompe à protons |
WO2015155297A1 (fr) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Combinaisons pharmaceutiques de dabigatran et d'antagonistes du récepteur h2 |
CN104230888A (zh) * | 2014-06-03 | 2014-12-24 | 长春工业大学 | 一种苯并咪唑化合物的制备方法 |
CN105218519A (zh) * | 2014-06-04 | 2016-01-06 | 天津药物研究院 | 一种达比加群酯中间体的制备方法 |
CN104003977B (zh) * | 2014-06-05 | 2016-04-13 | 雅本化学股份有限公司 | N-(2-氯甲基-1-甲基-1h-苯并咪唑-5-酰基)-n-(吡啶-2-基) -3-氨基丙酸乙酯的制备方法 |
DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
CN104045628B (zh) * | 2014-06-13 | 2019-04-09 | 深圳翰宇药业股份有限公司 | 苯并咪唑衍生物的纯化方法 |
CN105315257A (zh) * | 2014-06-24 | 2016-02-10 | 华仁药业股份有限公司 | 一种达比加群酯的合成及纯化方法 |
WO2016019849A1 (fr) * | 2014-08-06 | 2016-02-11 | 四川海思科制药有限公司 | Dérivé de carboalcoxy de dabigatran, son procédé de préparation, et son utilisation pharmaceutique |
WO2016019848A1 (fr) * | 2014-08-06 | 2016-02-11 | 四川海思科制药有限公司 | Dérivé thioester du dabigatran, son procédé de préparation et son utilisation pharmaceutique |
NO2721243T3 (fr) | 2014-10-01 | 2018-10-20 | ||
US10675276B2 (en) | 2014-11-03 | 2020-06-09 | Hangzhou Solipharma Co., Ltd. | Dosing preparation of dabigatran etexilate or a salt thereof and a preparation method thereof |
CN104592204B (zh) * | 2014-12-26 | 2017-05-17 | 华润赛科药业有限责任公司 | 达比加群衍生物及其制备方法和用途 |
CN104650037A (zh) * | 2014-12-30 | 2015-05-27 | 青岛黄海制药有限责任公司 | 一种达比加群酯的合成方法 |
TR201502223A2 (tr) | 2015-02-25 | 2016-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dronedaron ve dabigatranın farmasötik kombinasyonları. |
CN104628733A (zh) * | 2015-03-02 | 2015-05-20 | 中国药科大学 | 四氢苯并[4,5]咪唑并[1,2-a]吡嗪类凝血酶抑制剂 |
EP3310777B1 (fr) | 2015-06-19 | 2019-10-09 | Bristol-Myers Squibb Company | Diamides macrocycliques en tant q'inhibiteurs du facteur xia |
CN104987323B (zh) * | 2015-07-10 | 2017-08-22 | 浙江美诺华药物化学有限公司 | 一种达比加群酯的制备方法 |
WO2017013106A1 (fr) | 2015-07-20 | 2017-01-26 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Préparations pharmaceutiques de dabigatran sous forme de base libre |
ES2937156T3 (es) | 2015-07-29 | 2023-03-24 | Bristol Myers Squibb Co | Inhibidores macrocíclicos del factor XIa que llevan un grupo P2' no aromático |
JP6785838B2 (ja) | 2015-08-05 | 2020-11-18 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 新規な置換グリシン誘導のfxia阻害剤 |
CN105294651A (zh) * | 2015-09-23 | 2016-02-03 | 烟台东诚药业集团股份有限公司 | 一种用于合成制备达比加群酯脒化中间体的方法 |
CN106866626A (zh) * | 2015-12-14 | 2017-06-20 | 天津药物研究院有限公司 | 一种达比加群酯中间体的制备方法 |
CN105481831B (zh) * | 2015-12-16 | 2018-06-12 | 开封明仁药业有限公司 | 一种制备达比加群酯中间体的方法 |
WO2017111637A1 (fr) | 2015-12-23 | 2017-06-29 | Zaklady Farmaceutyczne Polpharma Sa | Composition pharmaceutique comprenant du dabigatran ou un sel pharmaceutiquement acceptable de celui-ci |
CN105566297A (zh) * | 2015-12-31 | 2016-05-11 | 哈药集团技术中心 | 一种达比加群酯甲磺酸盐的制备方法 |
EP3423458A1 (fr) | 2016-03-02 | 2019-01-09 | Bristol-Myers Squibb Company | Macrocycles diamide présentant une activité inhibitrice du facteur xia |
CN105669651B (zh) * | 2016-03-07 | 2018-03-06 | 山东罗欣药业集团股份有限公司 | 一种甲磺酸达比加群酯的制备工艺 |
CN106397400A (zh) * | 2016-04-14 | 2017-02-15 | 江苏康缘药业股份有限公司 | 一种达比加群酯的制备方法 |
TR201606697A2 (tr) | 2016-05-20 | 2017-12-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin yeni̇ oral farmasöti̇k formülasyonlari |
CN106349221A (zh) * | 2016-08-29 | 2017-01-25 | 常州市阳光药业有限公司 | 高纯度达比加群酯的制备方法 |
EP3332771A1 (fr) | 2016-12-07 | 2018-06-13 | Sanovel Ilac Sanayi ve Ticaret A.S. | Compositions de comprimé multicouche de dabigatran |
TR201617984A2 (tr) | 2016-12-07 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin farmasöti̇k kompozi̇syonlari |
JP2018184375A (ja) | 2017-04-27 | 2018-11-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法 |
WO2019004980A2 (fr) | 2017-05-10 | 2019-01-03 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions pharmaceutiques orales solides d'étéxilate de dabigatran |
TR201706848A2 (tr) | 2017-05-10 | 2018-11-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar |
CN109010249A (zh) * | 2017-06-08 | 2018-12-18 | 上海美悦生物科技发展有限公司 | 注射用达比加群酯药物组合物及其制备方法和用途 |
KR20190036857A (ko) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | 다비가트란 이텍실레이트를 포함하는 복합 캡슐제 |
TR201722186A2 (tr) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin farmasöti̇k kompozi̇syonlari |
TR201722323A2 (tr) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari |
TR201722630A2 (fr) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | |
CN111954532A (zh) * | 2018-04-13 | 2020-11-17 | 上海交通大学医学院附属瑞金医院 | 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物 |
CN108864047A (zh) * | 2018-07-02 | 2018-11-23 | 河南师范大学 | 一种非肽类凝血酶抑制剂达比加群酯的制备方法 |
EP3771465A1 (fr) | 2019-08-01 | 2021-02-03 | Zaklady Farmaceutyczne Polpharma SA | Composition pharmaceutique comprenant du dabigatran etexilate |
CN111606885A (zh) * | 2020-06-18 | 2020-09-01 | 安徽鼎旺医药有限公司 | 一种达比加群酯甲磺酸盐及其制备方法 |
CN113929661A (zh) * | 2020-06-29 | 2022-01-14 | 石药集团恩必普药业有限公司 | 一种达比加群酯中间体及其制备方法 |
EP4070658A1 (fr) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Utilisation de composés anticoagulants comme rodenticides |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675405A (en) * | 1984-09-21 | 1987-06-23 | American Home Products Corporation | Quinoline compounds as antiallergic and antithrombotic agents |
DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5416099A (en) * | 1991-10-29 | 1995-05-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
ZA928276B (en) * | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
CA2134192A1 (fr) * | 1993-11-12 | 1995-05-13 | Michael L. Denney | Antagonistes iib/iiia de la glycoproteine 5, 6-bicyclique |
-
1998
- 1998-01-15 PE PE1998000030A patent/PE121699A1/es not_active IP Right Cessation
- 1998-01-23 MY MYPI98000290A patent/MY129408A/en unknown
- 1998-02-16 CA CA002277949A patent/CA2277949C/fr not_active Expired - Lifetime
- 1998-02-16 AU AU63991/98A patent/AU742593C/en not_active Expired
- 1998-02-16 IL IL13081298A patent/IL130812A/en active Protection Beyond IP Right Term
- 1998-02-16 DK DK98909468T patent/DK0966454T3/da active
- 1998-02-16 CZ CZ0291599A patent/CZ297768B6/cs not_active IP Right Cessation
- 1998-02-16 NZ NZ337323A patent/NZ337323A/en not_active IP Right Cessation
- 1998-02-16 ES ES98909468T patent/ES2199426T4/es not_active Expired - Lifetime
- 1998-02-16 AT AT98909468T patent/ATE239712T1/de active
- 1998-02-16 BR BRPI9807843-7A patent/BR9807843B1/pt not_active IP Right Cessation
- 1998-02-16 SI SI9830479T patent/SI0966454T1/xx unknown
- 1998-02-16 PT PT98909468T patent/PT966454E/pt unknown
- 1998-02-16 SK SK1121-99A patent/SK285432B6/sk active Protection Beyond IP Right Term
- 1998-02-16 WO PCT/EP1998/000865 patent/WO1998037075A1/fr active IP Right Grant
- 1998-02-16 TR TR1999/02017T patent/TR199902017T2/xx unknown
- 1998-02-16 KR KR1019997007335A patent/KR100619458B1/ko active IP Right Review Request
- 1998-02-16 DE DE122008000020C patent/DE122008000020I1/de active Pending
- 1998-02-16 EP EP98909468A patent/EP0966454B1/fr not_active Expired - Lifetime
- 1998-02-16 EA EA199900746A patent/EA003697B1/ru active IP Right Grant
- 1998-02-16 RS YUP-387/99A patent/RS49686B/sr unknown
- 1998-02-16 CN CN98802623A patent/CN1088702C/zh not_active Expired - Lifetime
- 1998-02-16 EE EEP199900359A patent/EE04716B1/xx active Protection Beyond IP Right Term
- 1998-02-16 HU HU0001116A patent/HU223754B1/hu active Protection Beyond IP Right Term
- 1998-02-16 DE DE59808281T patent/DE59808281D1/de not_active Expired - Lifetime
- 1998-02-16 PL PL98335154A patent/PL195551B1/pl unknown
- 1998-02-16 JP JP53623498A patent/JP3343359B2/ja not_active Expired - Lifetime
- 1998-02-17 EG EG18498A patent/EG24144A/xx active
- 1998-02-17 CO CO98008407A patent/CO4920237A1/es unknown
- 1998-02-17 HR HR980082A patent/HRP980082B1/xx not_active IP Right Cessation
- 1998-02-18 AR ARP980100722A patent/AR010896A1/es active Pending
- 1998-02-18 TW TW087102265A patent/TW588047B/zh not_active IP Right Cessation
- 1998-05-06 SA SA98190047A patent/SA98190047B1/ar unknown
-
1999
- 1999-08-10 BG BG103655A patent/BG64558B1/bg active Active
- 1999-08-17 NO NO19993945A patent/NO313879B1/no not_active IP Right Cessation
-
2000
- 2000-07-10 HK HK00104207A patent/HK1025096A1/xx not_active IP Right Cessation
-
2008
- 2008-05-09 LT LTPA2008008C patent/LTC0966454I2/lt unknown
- 2008-05-14 LU LU91437C patent/LU91437I2/fr unknown
- 2008-05-28 NL NL300349C patent/NL300349I2/nl unknown
- 2008-06-06 FR FR08C0025C patent/FR08C0025I2/fr active Active
- 2008-07-31 NO NO2008012C patent/NO2008012I2/no not_active IP Right Cessation
-
2021
- 2021-02-05 NO NO2021005C patent/NO2021005I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR08C0025I2 (fr) | Heterocycles bicycliques disubstitues, production et utilisation comme medicaments | |
MA26549A1 (fr) | Medicaments | |
PT911340E (pt) | Isoquinolinas-3-carboxamidas substituidas, sua preparacao e utilizacao como farmacos | |
TR199801996A3 (tr) | Pirazol türevleri, üretimi ve ilaç olarak kullanimi | |
IL147133A0 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof | |
FR2735127B1 (fr) | Nouvelles piperazines heteroaromatiques utiles comme medicaments. | |
EE200000037A (et) | Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena | |
DE69814367D1 (de) | Filmueberzogene tabletten von oxacarbazepin | |
ATE243708T1 (de) | Substituierte imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate | |
HUP0200710A3 (en) | Benzimidazoles, production thereof and use thereof as medicaments | |
DE59905572D1 (de) | Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate | |
ID30116A (id) | Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya | |
ATE449786T1 (de) | Imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate | |
DK1017392T3 (da) | Lægemiddel | |
TR199801871A3 (tr) | Bifenilsulfonilsiyanamidler üretim yöntemi ve ilaç olarak kullanimlari. | |
DE69630391D1 (de) | Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung | |
ID24413A (id) | Turunan-turunan bifenil sebagai obat-obatan | |
PT1235809E (pt) | 1,2,3,4,5,6-hexa-hidro-2,6-metano-3-benzazocinas substituidas e sua utilizacao como medicamentos | |
ZA981275B (en) | Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions. | |
AU6087599A (en) | Disubstituted pyrrolidinones, medicaments containing these compounds, their use and the production thereof | |
BR1100782A (pt) | Fenilimidazolidinas substituìdas, sua aplicação como medicamentos e as composições farmacêuticas que as contêm | |
SE9602895D0 (sv) | Intag av mediciner | |
UA1246S (uk) | Таблетка фармацевтична | |
BR1100700A (pt) | Emprego de derivados de 4h-1-benzopiran-4-ona,novos derivados de 4h-1-benzopiran-4-ona emedicamentos contendo os mesmos | |
FR2770401B1 (fr) | Medicaments homeopathiques associant : antimonium crudum, antimonium tartaricum, natrum phosphoricum, adrenalinum, secale cornutum |